Canna Innov is targeting formulation and administration strategies
optimizing cannabinoid bioavailability and onset time. Our strategy allows for the expansion of physiological applications based on improved performance as well as cost-effective product diversification for a given API.
GMP Pharmaceutical company
Canna Innov has a close collaboration with Cana Laboratories, a Greek pharmaceutical company established in 1928. Its manufacturing site is EU-GMP licensed with batch release and repackaging possibilities.